TH78308A - A heterocyclic pyrazole derivative that reacts as a kinase inhibitor. - Google Patents

Abstract

DC60 (30/09/46) Bicyclopyrazole compound form (I) and its pharmaceutical salts as defined in the specification, the process for preparing these compounds, the set of compounds formed by combining various groups of these compounds, and pharmaceutical mixtures of these compounds are disclosed in this patent application. The compounds of this invention, as protein kinase inhibitors, have therapeutic benefits, for example, in the treatment of cancer. Bicyclopyrazole compound form (I) and its pharmaceutical salts as defined in the specification, the process for preparing these compounds, the set of compounds formed by combining various groups of these compounds, and pharmaceutical mixtures of these compounds are disclosed in this patent application. The compounds of this invention, as protein kinase inhibitors, have therapeutic benefits, for example, in the treatment of cancer.

Claims (17)

1. Bicyclopyrazole compounds, as formula (I) (chemical formula), where X is NR', O, S, SO or SO2, each symbol of R and R1, whether identical or different, has an independent meaning as a hydrogen atom or a selectable substitution group of R', -COR', -COOR', CONHR', -CONR'R", -SO2R', -SO2NHR' or -SO2NR'R", each symbol of R' and R", whether identical or different, has an independent meaning as a hydrogen or a C1-C6 alkyl chain, straight or branched chain, selectable substitution group, heterocyclic, aryl or aryl-C1-C6 alkyl. R2 is a selectable substitution group of R', -CH2OR' and OR', where R' has the meaning as defined above, and the pharmaceutical salts of this compound. 2. The substance as defined in Claim 1, where X is S, O is ; R is -CONHR'; R1 is -COR', -CONHR', -CONR'R", -SO2NHR' or -SO2NR'R", where each R' and R" symbol, whether identical or different, can be selected from hydrogen or C1-C6 alkyl chains, straight or branched chains that may be selected as substitutes, aryl or aryl-C1-C6 alkyl, R2 is hydrogen or the pharmaceutically viable salt of this substance. 3. The substance as defined in Claim 1, where X is S; R is -CONHR'; R1 is -CONHR' or -CONR'R", where each R' and R" symbol, whether identical or different, can be selected from hydrogen or C1-C6 alkyl straight chains or branched chains that may be selected to be substituted, aryl or aryl C1-C6 alkyl, R2 is hydrogen or the pharmaceutically viable salt of this substance. 4. Pharmaceutically usable formulation (I) or salt as defined in Claim 1 as defined in Example 6. 5. The formulation (I) or pharmaceutically usable salt as defined in claim 1, which is tertiarybutyl 3-amino-1H-thienneno[2,3-c]pyrazole-5-carboxylate. 6. Pharmaceutically usable formulation (I) or salt as defined in Claim 1 for use as a medicine. 7. The use of the formulation (I) or the pharmaceutically viable salt of this substance, as defined in Reputation 1, in the manufacture of medicines for the treatment of patients with illnesses caused by and/or related to altered (abnormally regulated) protein kinase activity. 8. Use of the bicyclopyrazole compound formulated (I) or its pharmaceutically viable salts as defined in Reputation 1 in the manufacture of drugs for the treatment of mammals, including humans, suffering from diseases caused by and/or related to altered (abnormally controlled) protein kinase activity. 9. The use of Claim 8, which states that diseases caused by and/or associated with altered protein inase activity, can be selected from a group comprising cancer, proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases, and neurodegenerative disorders. 10. The use of claim 9, which allows selection of cancer from a group comprising: carcinoma, squamous cell carcinoma, myeloid or lymphoid hematopoietic tumors, mesenchymal tumors, central and peripheral nervous system tumors, melanoma, seminoma, teratocarchimona, osteosarcoma, cerodermafixmentosum, keratoxanthoma, thyroid follicular cancer, and carbosis sarcoma. 11. The use of claim 9, which allows for the selection of proliferative abnormalities from a group comprising benign proliferative and prostatic proliferative tumors, hereditary benign tumors, probable colon tumors, neurofibromatosis, erythematosus, atherosclerosis-associated smooth cell proliferation, pulmonary fibrosis, arthritis, glomerular glomerulonephritis, and postoperative and recurrent vascular stenosis. 12. The use of claim 8 results in the inhibition of angiogenesis and metastasis of the tumor. 13. The use of the formulation (I) or the pharmaceutically viable salt of this substance, as defined in Reputation 1, in the manufacture of medicines for the treatment of diseases caused by and/or related to altered protein kinase activity in patients receiving concomitant, separate, or sequential anti-cancer treatments. 14. The process for preparing the formula (II) and pharmaceutically usable salts of this substance, which consists of: a) the reaction between the formula (II) (chemical formula) (II), where R1, R2, and X have the meanings defined in Reputation 1 and R3 are low molecular weight alkyl groups, with hydrazine or a salt of hydrazine to obtain formula (I), where R is hydrogen and R1, R2, and X have the meanings defined above, and if desired, b) the transformation of the obtained formula (I) into another form of formula (I), where R is not a hydrogen atom, and/or the desired transformation of the formula (I) into pharmaceutically usable salts of the substance, and/or the salts of formula (I) into free compounds of that salt. 15. A set of chemical compounds formed by the combination of various groups in different ways, consisting of members according to the formula (VIII) resin (chemical formula) (VIII), where X is NR', O, S, SO or SO2, each symbol of R and R1, identical or different, has an independent meaning as a hydrogen atom or a selectable substituted group of R', -COR', -COOR', CONHR', -CONR'R", -SO2R', -SO2NHR' or -SO2NR'R", each symbol of R' and R", identical or different, has an independent meaning as a hydrogen or a C1-C6 alkyl chain, straight or branched alkyl chain, heterocyclic, aryl or aryl-C1-C6 alkyl group. R2 is a selectable substituted group of R', -CH2OR' and OR'', where R' has the meaning as defined above; and pharmaceutical salts of this compound. 16. The set of materials in claim 15, in which the resin is a polystyrene resin, such as methyl isocyanate polystyrene resin. 17. A chemical compound consisting of two or more derivatives of formula (I), where X is NR', O, S, SO, or SO2, each symbol of R and R1, either identical or different, independently represents a hydrogen atom or a selective substitution group of R', -COR', -COOR', CONHR', -CONR'R", -SO2R', -SO2NHR', or -SO2NR'R", each symbol of R' and R", either identical or different, independently represents a hydrogen atom or a selective substitution group of straight or branched alkyl chains, heterocyclic, aryl, or aryl-C1-C6 alkyl chains. R2 is a selective substitution group of R', -CH2OR', and OR', where R' has the meaning as defined above, and the pharmaceutical salts of this compound.